Matching Wits with Melanoma Brain Metastases: From Biology to Therapeutics
Author:
- 30 October 2014
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 20 (21) , 5346-5348
Abstract
Melanoma brain metastases (MBM) present a significant clinical challenge. Molecular profiling of MBM is useful to identify molecular pathways, such as the PI3K pathway, that are specifically and differentially altered in MBM. Therapeutic studies should recruit patients with MBM and prospective tissue collection will lay the foundation for further advances. Clin Cancer Res; 20(21); 5346–8. ©2014 AACR.Keywords
This publication has 11 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Pathologic and gene expression features of metastatic melanomas to the brainCancer, 2013
- Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastasesCancer Medicine, 2012
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With MelanomaJournal of Clinical Oncology, 2012
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialThe Lancet, 2012
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialThe Lancet Oncology, 2012
- Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center ExperienceClinical Cancer Research, 2011
- Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic MelanomaClinical Cancer Research, 2009